LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
Shares of LivaNova Plc (NASDAQ:LIVN) Tuesday climbed along with several other big stocks.
LivaNova Plc（納斯達克代碼：LIVN）的股價週二上漲，與其他幾隻大股票一起。
There is high visibility into the company's near-term baseline growth, with potential upside to revenue and earnings from "new product cycles and pipeline optionality," according to Goldman Sachs.
高盛表示，對該公司近期基線增長有很高的可見度，從「新產品週期和管道選擇性」中獲得營收和收益的潛在增長。
Analyst David Roman initiated coverage of LivaNova with a Buy rating and price target of $65.
分析師David Roman開始覆蓋LivaNova，評級爲買入，目標股價爲65美元。
The LivaNova Thesis: LivaNova's earnings had been under pressure due to strategic shifts in the company's business and pipeline setbacks. Roman said in the initiation note.
LivaNova 研究報告：由於公司業務戰略轉變和管道挫折，LivaNova的收益一直面臨壓力。Roman在初始報告中表示。
Check out other analyst stock ratings.
查看其他分析師的股票評級。
With a greater focus on commercial execution, "given the recent transition in corporate strategy," LivaNova could generate consistent results and margin profile improvement, which would make its period of underperformance fade "into the rearview mirror," he added.
隨着公司戰略的最新轉變，重點更加集中在商業執行力上，LivaNova有望實現穩定的業績和利潤率改善，這將使其長期表現的不佳「漸行漸遠」，他補充道。
From here, LivaNova's base business is poised to generate around 5% revenue growth from "stable-end markets and de novo neuromodulation implants as well as a near-term bolus of growth from an identifiable product cycle upgrade in cardiopulmonary (52% of sales)," the analyst wrote.
分析師表示，從當前開始，由於「穩定的終端市場和德諾神經調節植入物以及心肺升級產品週期將爲營收增長帶來短期增長（銷售額的52％）」，LivaNova的基本業務將有望實現約5%的營收增長。
Sustained revenue growth, improved mix, and more targeted cost management could drive "outsized EPS growth" of around 14% through 2027, he further stated.
持續的營收增長、改善的產品組合和更有針對性的成本管理可能會推動到2027年的「超額每股收益增長」約14％，他進一步表示。
LIVN Price Action: Shares of LivaNova were up 0.6% to $53.53 at the time of publication on Friday.
livanova股價走勢：在週五出版時，LivaNova的股價上漲了0.6%，至53.53美元。
Read More:
閱讀更多：
- Medtronic Recalls MiniMed Pump Due To Battery Life Concerns
- 美敦力因電池續航問題召回MiniMed泵。
Image created using artificial intelligence via Midjourney.
圖像由Midjourney通過人工智能創建。
譯文內容由第三人軟體翻譯。
